CD8A and neoplasm: Finally, another AND gate design (directed at T cell functionality) called CD8-guided TCE (Figure 3) was recently unveiled by AstraZeneca consisting of a CD20xTCRxCD8 trispecific TCE (AZD5492) designed to selectively engage CD8+ T cells and avoid CD4+ T cells, resulting in potent anti-tumor activity and a significantly decreased cytokine release profile (197).